Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Health and Quality of Life Outcomes
Published in: Health and Quality of Life Outcomes 1/2011

Open Access 01-12-2011 | Research

The comparative burden of mild, moderate and severe Fibromyalgia: results from a cross-sectional survey in the United States

Authors: Caroline Schaefer, Arthi Chandran, Meghan Hufstader, Rebecca Baik, Michael McNett, Don Goldenberg, Robert Gerwin, Gergana Zlateva

Published in: Health and Quality of Life Outcomes | Issue 1/2011

Login to get access

Abstract

Background

Fibromyalgia (FM) is characterized by chronic, widespread pain, fatigue, and other symptoms; yet few studies have comprehensively assessed its humanistic burden. This observational study evaluates the impact of FM severity on patients' symptoms, health-related quality of life (HRQoL), and productivity in the United States.

Methods

203 FM subjects were recruited from 20 physician offices. Subjects completed a questionnaire including the EuroQol 5D (EQ-5D), Fibromyalgia Impact Questionnaire (FIQ), Multidimensional Assessment of Fatigue (MAF), Medical Outcomes Study Sleep Scale (MOS-SS), and Hospital Anxiety and Depression Scale (HADS) and questions about demographics, pain and other symptoms, HRQoL and productivity. FIQ total scores were used to define FM severity, with 0- < 39, 39- < 59, and 59-100, representing mild, moderate, and severe FM, respectively. Sites recorded subjects' clinical characteristics and FM treatment on case report forms using medical records. Summary statistics were calculated for continuous variables and frequency distributions for categorical variables. Differences across FM severity groups were evaluated using the Kruskal-Wallis or Chi-square tests. Statistical significance was evaluated at the 0.05 level.

Results

Mean (SD) age was 47.9 (10.9); 95% were female. Most (92%) were prescribed medication for FM; 24% and 66% reported moderate and severe FM, respectively. Mean (SD) scores were: 6.3 (2.1) for pain intensity; 0.35 (0.35) for EQ-5D; 30.7 (14.2) for MAF; 57.5 (18.4) for MOS-SS Sleep Problems Index; 10.2 (4.8) for HADS anxiety and 9.4 (4.4) for HADS depression. Subjects with worse FM severity reported significantly increased pain severity, HRQoL, fatigue, sleep disturbance, anxiety and depression (p < 0.001). Overall, 50% of subjects reported some disruption in their employment due to FM; this differed across severity levels (p < 0.001). Employed subjects missed a mean (SD) of 1.8 (3.9) workdays during the past 4 weeks; this also differed across severity levels (p = 0.03).

Conclusions

FM imposes a substantial humanistic burden on patients in the United States, and leads to substantial productivity loss, despite treatment. This burden is higher among subjects with worse FM severity.
Appendix
Available only for authorised users
Literature
1.
Wolfe F, Ross K, Anderson J, Russell IJ, Hebert L: The prevalence and characteristics of fibromyalgia in the general population. Arthritis Rheum 1995, 38: 19–28. 10.1002/art.1780380104PubMedCrossRef
2.
Weir PT, Harlan GA, Nkoy FL, Jones SS, Hegmann KT, Gren LH, Lyon JL: Incidence of Fibromyalgia and Its Associated Comorbidities. Journal of Clinical Rheumatology 2006,12(3):124–128. 10.1097/01.rhu.0000221817.46231.18PubMedCrossRef
3.
Jones J, Rutledge DN, Jones KD, Matallana L, Rooks DS: Self-Assessed Physical Function Levels of Women with Fibromyalgia: A National Study. Women's Health Issues 2008, 18: 406–412. 10.1016/j.whi.2008.04.005PubMedCrossRef
4.
Arnold LM, Hudson JI, Keck PE Jr, Auchenback MB, Javaras KN, Hess EV: Comorbidity of fibromyalgia and psychiatric disorders. J Clin Psychiatry 2006, 67: 1219–1225. 10.4088/JCP.v67n0807PubMedCrossRef
5.
White KP, Speechley M, Harth M, Ostbye T: The London Fibromyalgia Epidemiology Study: Comparing self-reported function and work disability in 100 community cases of fibromyalgia syndrome versus controls in London, Ontario. Arthritis and Rheumatism 1999,42(1):76–83. 10.1002/1529-0131(199901)42:1<76::AID-ANR10>3.0.CO;2-GPubMedCrossRef
6.
Park DC, Glass JM, Minear M, Crofford LJ: Cognitive Function in Fibromyalgia Patients. Arthritis and Rheumatism 2001,44(9):2125–2133. 10.1002/1529-0131(200109)44:9<2125::AID-ART365>3.0.CO;2-1PubMedCrossRef
7.
Annemans L, Le Lay K, Taïeb C: Societal and patient burden of fibromyalgia syndrome. Pharmacoeconomics 2009,27(7):547–559. 10.2165/11313650-000000000-00000PubMedCrossRef
8.
Gormsen L, Rosenberg R, Bach FW, Jensen TS: Depression, anxiety, health-related quality of life and pain in patients with chronic fibromyalgia and neuropathic pain. Eur J Pain 2010,14(2):127. e1–8PubMedCrossRef
9.
Moore RA, Straube S, Paine J, Phillips CJ, Derry S, McQuay HJ: Fibromyalgia: Moderate and substantial pain intensity reduction predicts improvement in other outcomes and substantial quality of life gain. Pain 2010,149(2):360–364. 10.1016/j.pain.2010.02.039PubMedCrossRef
10.
Robinson RL, Birnbaum HG, Morley MA, Sisitsky T, Greenberg PE, Claxton AJ: Economic cost and epidemiological characteristics of patients with fibromyalgia claims. J Rheumatol 2003,30(6):1318–1325.PubMed
11.
White LA, Birnbaum HG, Kaltenboeck A, Tang J, Mallett D, Robinson RL: Employees with fibromyalgia: medical comorbidity, healthcare costs, and work loss. J Occup Environ Med 2008, 50: 13–24. 10.1097/JOM.0b013e31815cff4bPubMedCrossRef
12.
Mease PJ, Clauw DJ, Arnold LM, et al.: Fibromyalgia syndrome. J Rheumatol 2005, 32: 2270–2277.PubMed
13.
Perrot S, Winkelmann A, Dukes E, Xu X, Schaefer C, Ryan K, Chandran A, Sadosky A, Zlateva G: Characteristics of patients with fibromyalgia in France and Germany. Int J Clin Pract 2010,64(8):1100–1108. 10.1111/j.1742-1241.2010.02418.xPubMedCrossRef
14.
Wolfe F, Michaud K, Li T, Katz RS: EQ-5D and SF-36 quality of life measures in systemic lupus erythematosus: comparisons with rheumatoid arthritis, noninflammatory rheumatic disorders, and fibromyalgia. J Rheumatol 2010,37(2):296–304. 10.3899/jrheum.090778PubMedCrossRef
15.
Bigatti SM, Hernandez AM, Cronan TA, Rand KL: Sleep disturbances in fibromyalgia syndrome: relationship to pain and depression. Arthritis Rheum 2008,59(7):961–967. 10.1002/art.23828PubMedCentralPubMedCrossRef
16.
Cappelleri JC, Bushmakin AG, McDermott AM, Dukes E, Sadosky A, Petrie CD, Martin S: Measurement properties of the Medical Outcomes Study Sleep Scale in patients with fibromyalgia. Sleep Med 2009,10(7):766–770. 10.1016/j.sleep.2008.09.004PubMedCrossRef
17.
Sinclair JD, Starz TW, Turk DC: The Manual Tender Point Survey. Pittsburgh, PA: University of Pittsburgh Medical Center. Copyright 1997 by the University of Pittsburgh Medical Center, Center for Continuing Education in the Health Sciences. Instructions adapted from The Manual Tender Point Survey, by JD Sinclair TW Starz and DC Turk; 1997. Instructions adapted from The Manual Tender Point Survey, by JD Sinclair TW Starz and DC Turk, accessed on September 2, 2011. [http://​www.​fmaware.​org/​News2eb58.​html?​page=​NewsArticle&​id=​6263]
18.
EuroQol Group: EuroQol: a new facility for the measurement of health related quality of life. Health Policy 1990,16(3):199–208.CrossRef
19.
Burckhardt CS, Clark SR, Bennett RM: The Fibromyalgia Impact Questionnaire: Development and validation. J Rheumatol 1991,18(5):728–734.PubMed
20.
Bennett RM, Bushmakin AG, Cappelleri JC, Zlateva G, Sadosky A: Minimal Clinically Important Difference in the Fibromyalgia Impact Questionnaire. J Rheumatol 2009,36(6):1304–1311. 10.3899/jrheum.081090PubMedCrossRef
21.
Belza B, Henke C, Yelin E, Epstein W, Gilliss C: Correlates of fatigue in older adults with rheumatoid arthritis. Nursing Research 1993,42(2):93–99.PubMedCrossRef
22.
Hays RD, Stewart AL: Sleep measures. In Measuring Functioning and Well-being: the Medical Outcomes Study Approach. Edited by: Stewart AL, Ware JE, Durham, NC. Duke University Press; 1992:235–259.
23.
Zigmond A, Snaith RP: The Hospital Anxiety and Depression Scale. Acta Psychiatrica Scandinavica 1983, 67: 361–370. 10.1111/j.1600-0447.1983.tb09716.xPubMedCrossRef
24.
Zelman D, Dukes E, Brandenburg N, Bostrom A, Gore M: Identification of cut-points for mild, moderate and severe pain due to diabetic peripheral neuropathy. Pain 2005,115(1–2):29–36. 10.1016/j.pain.2005.01.028PubMedCrossRef
25.
26.
Hays RD, Martin SA, Sesti AM, Spritzer KL: Psychometric properties of the Medical outcomes Study Sleep measure. Sleep Med 2005,6(1):41–44. 10.1016/j.sleep.2004.07.006PubMedCrossRef
27.
Moldofsky H: The significance, assessment, and management of nonrestorative sleep in fibromyalgia syndrome. CNS Spectr 2008,13(3):22–26.PubMed
28.
Fryback DG, Dunham NC, Palta M, Hanmer J, Buechner J, Cherepanov D, Herrington SA, Hays RD, Kaplan RM, Ganiats TG, Feeny D, Kind P: U.S. Norms from six generic health-related quality-of-life indexes from the National Health Measurement Study. Med Care 2007,45(12):1162–70. 10.1097/MLR.0b013e31814848f1PubMedCentralPubMedCrossRef
29.
Wolfe F, Anderson J, Harkness D, Bennett RM, Caro XJ, Goldenberg DL, Russell IJ, Yunus MB: Health status and disease severity in fibromyalgia. Arth Rheum 1997,40(9):1571–1579. 10.1002/art.1780400905CrossRef
30.
Salaffi F, Sarzi-Puttini P, Girolimetti R, Atzeni F, Gasparini S, Grassi W: Health-related quality of life in fibromyalgia patients: a comparison with rheumatoid arthritis patients and the general population using the SF-36 health survey. Clin Exp Rheumatol 2009,27(5 Suppl 56):S67–74.PubMed
31.
Hoffman DL, Dukes EM: The health status burden of people with fibromyalgia: a review of studies that assessed health status with the SF-36 or the SF-12. International Journal of Clinical Practice 2008,62(1):115–126.PubMedCentralPubMedCrossRef
Metadata
Title
The comparative burden of mild, moderate and severe Fibromyalgia: results from a cross-sectional survey in the United States
Authors
Caroline Schaefer
Arthi Chandran
Meghan Hufstader
Rebecca Baik
Michael McNett
Don Goldenberg
Robert Gerwin
Gergana Zlateva
Publication date
01-12-2011
Publisher
BioMed Central
Published in
Health and Quality of Life Outcomes / Issue 1/2011
Electronic ISSN: 1477-7525
DOI
https://doi.org/10.1186/1477-7525-9-71

Other articles of this Issue 1/2011

Health and Quality of Life Outcomes 1/2011 Go to the issue

Research

Spinsterhood and its impact on disease features in women with rheumatoid arthritis

Research

Mapping of the Insomnia Severity Index and other sleep measures to EuroQol EQ-5D health state utilities

Research

Heath-related quality of life in thyroid cancer patients following radioiodine ablation

Research

Development and validation of a short version of the Assessment of Chronic Illness Care (ACIC) in Dutch Disease Management Programs

Research

Differences in demographic composition and in work, social, and functional limitations among the populations with unipolar depression and bipolar disorder: results from a nationally representative sample

Research

Oral Health-Related Quality of Life among a large national cohort of 87,134 Thai adults